Michael R. McClung

35.5k total citations · 8 hit papers
281 papers, 22.8k citations indexed

About

Michael R. McClung is a scholar working on Orthopedics and Sports Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Michael R. McClung has authored 281 papers receiving a total of 22.8k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Orthopedics and Sports Medicine, 175 papers in Oncology and 108 papers in Molecular Biology. Recurrent topics in Michael R. McClung's work include Bone health and osteoporosis research (218 papers), Bone health and treatments (171 papers) and Bone Metabolism and Diseases (99 papers). Michael R. McClung is often cited by papers focused on Bone health and osteoporosis research (218 papers), Bone health and treatments (171 papers) and Bone Metabolism and Diseases (99 papers). Michael R. McClung collaborates with scholars based in United States, United Kingdom and Australia. Michael R. McClung's co-authors include William D. Leslie, Juliet Compston, Paul D. Miller, E. Michael Lewiecki, Richard Eastell, Michael A. Bolognese, Steven R. Cummings, Claus Christiansen, Javier San Martín and Cesar Libanati and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Michael R. McClung

275 papers receiving 22.0k citations

Hit Papers

Denosumab for Prevention of Fractures in Postmenopausal W... 2005 2026 2012 2019 2009 2019 2014 2006 2010 500 1000 1.5k 2.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
    2009 2.4k citations Steven R. Cummings, Javier San Martín et al. profile →
  2. Osteoporosis
    2019 1.6k citations Michael R. McClung et al. profile →
  3. Romosozumab in Postmenopausal Women with Low Bone Mineral Density
    2014 886 citations Michael R. McClung, Michael A. Bolognese et al. profile →
  4. Denosumab in Postmenopausal Women with Low Bone Mineral Density
    2006 886 citations Michael R. McClung, E. Michael Lewiecki et al. profile →
  5. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards
    2010 865 citations Richard Eastell, Michael R. McClung et al. Osteoporosis International profile →
  6. American Association of Clinical Endocrinologists/American College of Endocrinology Clinical Practice Guidelines for the Diagnosis and Treatment of Postmenopausal Osteoporosis—2020 Update
    2020 659 citations Steven M. Petak, E. Michael Lewiecki et al. Endocrine Practice profile →
  7. Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use
    2005 555 citations David W. Dempster, Michael R. McClung et al. Endocrine Reviews profile →
  8. Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension
    2017 458 citations Steven R. Cummings, Serge Ferrari et al. Journal of Bone and Mineral Research profile →

Peers

Michael R. McClung
E. Michael Lewiecki United States
Felicia Cosman United States
Jacques P. Brown Canada
Juliet Compston United Kingdom
Paul D. Miller United States
Nelson B. Watts United States
Ethel S. Siris United States
Eugène McCloskey United Kingdom
Christian Roux France
Robert Lindsay United States
E. Michael Lewiecki United States
Michael R. McClung
Citations per year, relative to Michael R. McClung Michael R. McClung (= 1×) peers E. Michael Lewiecki

Countries citing papers authored by Michael R. McClung

Since Specialization
Citations

This map shows the geographic impact of Michael R. McClung's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael R. McClung with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael R. McClung more than expected).

Fields of papers citing papers by Michael R. McClung

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael R. McClung. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael R. McClung. The network helps show where Michael R. McClung may publish in the future.

Co-authorship network of co-authors of Michael R. McClung

This figure shows the co-authorship network connecting the top 25 collaborators of Michael R. McClung. A scholar is included among the top collaborators of Michael R. McClung based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael R. McClung. Michael R. McClung is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Keaveny, Tony M., Annette L. Adams, Eric Orwoll, et al.. (2025). Improved prediction of hip fracture using multi-faceted biomechanical computed tomography. Journal of Bone and Mineral Research.
2.
Cosman, Felicia, et al.. (2024). Romosozumab followed by denosumab versus denosumab only: a post hoc analysis of FRAME and FRAME extension. Journal of Bone and Mineral Research. 39(9). 1268–1277. 8 indexed citations
3.
Keaveny, Tony M., Annette L. Adams, Eric Orwoll, et al.. (2024). Osteoporosis treatment prevents hip fracture similarly in both sexes: the FOCUS observational study. Journal of Bone and Mineral Research. 39(10). 1424–1433. 7 indexed citations
4.
Lewiecki, E. Michael, John P. Bilezikian, Amanda Clark, et al.. (2024). Proceedings of the 2024 Santa Fe Bone Symposium: Update on the Management of Osteoporosis and Rare Bone Diseases. Journal of Clinical Densitometry. 28(1). 101559–101559. 1 indexed citations
5.
Chotiyarnwong, Pojchong, Eugène McCloskey, Richard Eastell, et al.. (2020). A Pooled Analysis of Fall Incidence From Placebo-Controlled Trials of Denosumab. Journal of Bone and Mineral Research. 35(6). 1014–1021. 25 indexed citations
6.
7.
Reginster, Jean‐Yves, Michael R. McClung, David A. Cox, et al.. (2010). Effects of arzoxifene on fracture incidence in postmenopausal women with osteoporosis or with low bone mass. Open Repository and Bibliography (University of Liège). 2 indexed citations
8.
Dempster, David W., J. A. Eisman, S. L. Greenspan, et al.. (2010). Phase 3 Fracture Trial of Odanacatib for Osteoporosis - Study Design. Endocrine Reviews. 31(3). 1 indexed citations
9.
Cummings, Steven R., Javier San Martín, Michael R. McClung, et al.. (2009). Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. Obstetrical & Gynecological Survey. 64(12). 805–807. 41 indexed citations
10.
McClung, Michael R., et al.. (2007). Assessing Fracture Risk in Individual Patients. Journal watch. 2007. 1 indexed citations
11.
McClung, Michael R., E. Michael Lewiecki, Stanley Cohen, et al.. (2006). Denosumab in Postmenopausal Women With Low Bone Mineral Density. Obstetrical & Gynecological Survey. 61(6). 384–386. 16 indexed citations
12.
Bonnick, Sydney Lou, Kenneth G. Saag, Douglas P. Kiel, et al.. (2006). Comparison of Weekly Treatment of Postmenopausal Osteoporosis with Alendronate Versus Risedronate Over Two Years. Obstetrical & Gynecological Survey. 62(1). 35–36. 5 indexed citations
13.
Cosman, Felicia, Michael R. McClung, Clifford J. Rosen, et al.. (2005). Rationale and design of the MOTION study (monthly oral therapy with ibandronate for osteoporosis intervention).. Journal of Bone and Mineral Research. 20. 2 indexed citations
14.
Gallagher, John C., David J. Baylink, Ruth Freeman, & Michael R. McClung. (2001). Prevention of Bone Loss with Tibolone in Postmenopausal Women: Results of Two Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Studies. The Journal of Clinical Endocrinology & Metabolism. 86(10). 4717–4726. 94 indexed citations
15.
Hodgson, Stephen F., John P. Bilezikian, B.L. Clarke, et al.. (2001). American Association of Clinical Endocrinologists 2001 Medical Guidelines for Clinical Practice for the Prevention and Management of Postmenopausal Osteoporosis.. Endocrine Practice. 7(4). 293–312. 109 indexed citations
16.
McClung, Michael R., Richard Eastell, W. Bensen, et al.. (2000). Risedronate reduces hip fracture risk in elderly women with osteoporosis. Open Repository and Bibliography (University of Liège). 5 indexed citations
17.
McClung, Michael R.. (2000). Clinical risk factors and evaluation of the risk of osteoporosis in clinical practice.. PubMed. 151(5). 392–8. 13 indexed citations
18.
Miller, P. D., C. Roux, Michael R. McClung, et al.. (1999). Risedronate reduces hip fractures in patients with low femoral neck bone mineral density. Open Repository and Bibliography (University of Liège). 6 indexed citations
19.
McClung, Michael R., et al.. (1999). Risedronate is well-tolerated in women with osteoporosis. Open Repository and Bibliography (University of Liège). 1 indexed citations
20.
Kleerekoper, Michael, Ethel S. Siris, & Michael R. McClung. (1999). The bone and mineral manual : a practical guide. Academic Press eBooks. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by E. Michael Lewiecki Breakdown of academic impact, for papers by Felicia Cosman Breakdown of academic impact, for papers by Jacques P. Brown Breakdown of academic impact, for papers by Juliet Compston Breakdown of academic impact, for papers by Paul D. Miller Breakdown of academic impact, for papers by Nelson B. Watts Breakdown of academic impact, for papers by Ethel S. Siris Breakdown of academic impact, for papers by Eugène McCloskey Breakdown of academic impact, for papers by Christian Roux Breakdown of academic impact, for papers by Robert Lindsay
Rankless by CCL
2026